Cardiff Oncology (NASDAQ:CRDF) is one of the biggest laggards in today’s trade after the company announced it will not fund future development focused on metastatic castrate-resistant prostate cancer (mCRPC).
Cardiff also provided other pipeline updates. It plans to conduct a Phase 2 trial (ONSEMBLE) of onvansertib in second-line RAS mutated mCRC. ONSEMBLE aims to demonstrate the contribution of onvansetib against standard-of-care and validate results from the Phase 1b/2 trials. This trial will also seek to confirm the optimal dose of the drug.
Further, the company will also continue evaluating onvansertib’s potential uses for additional indications
Read full Disclosure
